Vaccines
Data published in bioRxiv confirmed previous findings suggesting mucosal vaccines could reduce transmission of airborne viruses such as COVID-19 and flu more than injectable vaccinesStudy suggests mucosal vaccines may protect not only vaccinated, but also unvaccinated animals Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Oct. 7, 2021 /PRNewswire/ — A Duke University-led study published in bioRxiv showed that Vaxart,…
Read MoreExcerpt from the Press Release: BENGALURU, Oct 6 (Reuters) – Bharat Biotech said on Wednesday it had submitted data from its COVID-19 vaccine trial in children aged 2 to 18 years to India’s drug regulator, becoming the country’s first company to have tested its shot in very young children. The South Asian country is turning…
Read MoreNew preclinical data demonstrate VBI-2905 induced robust neutralizing and antibody binding activity, as a 2-dose course and as a single booster dose, against COVID-19 and variants of concern including Beta and Delta– Data also demonstrate trivalent VBI-2901 induced robust and consistent levels of immunity against the ancestral COVID-19 strain and a panel of variants including…
Read More– Global Phase 2/3 SPECTRA Trial enrolled over 30,000 adult and elderly participants across 4 continents; 100% of SARS-CoV-2 strains observed in efficacy analysis were variants– 100% efficacy against severe COVID-19 and hospitalizations, and 84% efficacy against moderate-to-severe COVID-19 caused by any strain of SARS-CoV-2– Favorable safety profile; no significant differences in systemic adverse events…
Read MoreELI-005, containing the Amphiphile vaccine adjuvant AMP-CpG, induced >25-fold higher antigen-specific T cells in the peripheral blood and exhibited potent killing of antigen-positive targets in vivo that were maintained for >5 months after vaccination Vaccine responses were highly cross-reactive to SARS-CoV-2 variants of concern Antibody responses favored TH1 isotypes with titers 265-fold higher than natural convalescent patient…
Read MoreNews follows recent regulatory authorizations to proceed with the trial in Brazil and the PhilippinesINOVIO and partner Advaccine are collaborating on the global Phase 3 trial in regions underserved by COVID-19 vaccines; to focus on Latin America, Asia, and Africa PLYMOUTH MEETING, Pa., Sept. 22, 2021 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on…
Read MoreSAN DIEGO–(BUSINESS WIRE)–Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that Arcturus’ President & CEO, Joseph Payne, met with the President of Vietnam, Nguyen Xuan Phuc, and the…
Read MoreExcerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced Health Canada has approved the New Drug Submission (NDS-CV) for SPIKEVAX™ (elasomeran mRNA vaccine), which has been known as COVID-19 Vaccine Moderna, for active immunization to prevent COVID-19 in individuals 12 years…
Read MoremRNA-1273 at 50 µg dose level induced robust antibody responses of more than 40x against the Delta variant (B.1.617.2) CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it has initiated its submission to the U.S. Food and Drug Administration (FDA) for the evaluation of a booster dose…
Read MoreSoligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates
Excerpt from the Press Release: PRINCETON, N.J., Aug. 18, 2021 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive data demonstrating the efficacy of multiple filovirus vaccine candidates in NHPs, including thermostabilized multivalent vaccines…
Read More